Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials

HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on the design of its TIME-1 clinical trial, a pivotal Phase 3 trial of its Hsp90 inhibitor tanespimycin as a treatment for patients with multiple myeloma. Through the FDA's Special Protocol Assessment (SPA) process, Kosan and the FDA have reached agreement on overall protocol design, primary efficacy endpoints and data analysis as well as aspects of expected labeling if the data from the pivotal trial are supportive and tanespimycin is approved by the FDA. This pivotal Phase 3 protocol, as well as the overall development program, have also completed the "Scientific Advice" process with the centralized European Medicines Agency (EMEA).

Kosan's registration program for tanespimycin, called Tanespimycin in Myeloma Evaluation or TIME, has been initiated and includes two clinical trials: TIME-1 and TIME-2. TIME-1 is a pivotal Phase 3 trial to be conducted in a first-relapse patient population. TIME-1 will evaluate the clinical benefit of adding tanespimycin to bortezomib and compare these results to those seen with single-agent bortezomib. The Special Protocol Assessment Kosan has completed applies to the TIME-1 trial. TIME-2, which is designed to be supportive of the TIME-1 trial, is a Phase 2/3 trial in patients with relapsed-refractory disease. The TIME-2 trial also has the potential to support registration in the relapsed-refractory setting. Kosan has initiated the TIME-2 trial, which is enrolling patients, and expects to init
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma ... it will report its third quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:10/17/2014)... 2014  Training market researchers to spot and ... in today,s highly competitive global marketplace. As resources ... effectively and efficiently produce high performing analysts, regardless ... Effective training programs can help these ... internal clients by developing analysts who can drive ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
(Date:10/19/2014)... 2014 Hastings and Hastings, a Phoenix ... service throughout the greater Phoenix area and across Arizona ... regard to catastrophic automobile accidents. Statistics have indicated a ... throughout Arizona. As such, Hastings and Hastings has seen ... for those who have been injured through no fault ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... 2014 Recently, Top10BestSEOHosting.com has unveiled ... JustHost, GoDaddy and HostMonster are the best VPS ... Private Server) is the method of partitioning a ... which has the appearance and capabilities of running ... the site pays close attention to VPS products ...
(Date:10/19/2014)... NC (PRWEB) October 19, 2014 ... building program has just been released to the ... the online body building and fitness community. The ... attention of DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative ... experience of hitting what is commonly known as ...
(Date:10/19/2014)... disease that causes inflammation in the spinal joints ... the ancient Egyptian royal families. Now a new ... a journal of the American College of Rheumatology ... spinal condition called diffuse idiopathic skeletal hyperostosis (DISH) ... early 20th Dynasties. , Ankylosing spondylitis is ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... R.I. Researchers at Rhode Island Hospital have created ... effects of anesthetic agents (the substances used to block ... cardiac death. The researchers also found that some anesthetic ... upcoming issue of the American Journal of Physiology ...
... Musculoskeletal Center, NEW YORK, Oct. 27 ... government, medical and civic communities will,gather together to ... long-serving board member and philanthropist Mrs. Norma Smith, ... Gala. This event at the,Waldorf=Astoria will be emceed ...
... Peter Saltonstall,president of the National Organization for ... Administration,s new Compassionate Allowances,initiative "an outstanding achievement" ... diseases., The initiative announced today will ... with any of 25 rare diseases and ...
... for Business Impact for the development of an automated process to ... , ... Irvine, CA (Vocus) October 27, 2008 -- ... , , , ,LifeMasters Supported SelfCare, Inc. is strengthening its health ...
... advise their patients to quit smoking, but few providers ... the cessation process. New research presented at CHEST 2008, ... College of Chest Physicians (ACCP), shows that 87 percent ... 5 hours of training on tobacco dependence and less ...
... Findings Presented at the American Dietetic Association,s Food ... ... 27 According to new data presented,yesterday at the American ... Chicago, pistachios -- when paired with a,healthy diet -- significantly ...
Cached Medicine News:Health News:Effects of anesthesia on the heart 2Health News:Effects of anesthesia on the heart 3Health News:Norma Smith and Dr. Steven A. Stuchin honored at 2008 Founders Gala for NYU Hospital for Joint Diseases 2Health News:New Compassionate Allowances for Social Security Disability Represent 'Outstanding Achievement,' NORD Says 2Health News:LifeMasters Receives 2008 Vision Award for Business Impact 2Health News:LifeMasters Receives 2008 Vision Award for Business Impact 3Health News:Physicians lack smoking cessation training 2Health News:Physicians lack smoking cessation training 3Health News:Latest Pistachio Study Reveals Significant Reduction in Markers of Inflammation - an Emerging Risk Factor in Heart Disease 2Health News:Latest Pistachio Study Reveals Significant Reduction in Markers of Inflammation - an Emerging Risk Factor in Heart Disease 3Health News:Latest Pistachio Study Reveals Significant Reduction in Markers of Inflammation - an Emerging Risk Factor in Heart Disease 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: